Eli Lilly (LLY) Would Be Up More If The Market Weren't That Bad, Says Jim Cramer

We recently published 10 Stocks on Jim Cramer’s Radar. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed.

Eli Lilly and Company (NYSE:LLY) continues to be one of Cramer’s top pharmaceutical stocks. He has consistently discussed the firm in 2025 and praised it on several fronts. These include Eli Lilly and Company (NYSE:LLY)’s weight loss drugs, the firm’s plans to establish a robust manufacturing process in America, and new drugs in its pipeline. However, more recently, Cramer has admitted that the firm needs some catalysts for the shares to make further gains. Here is what he said about Eli Lilly and Company (NYSE:LLY) in this appearance before interviewing the firm’s CEO, David Ricks:

“I’ve followed Dave Ricks for a long time. Shares of Eli Lilly are on the move. Company blew past the estimates for the third quarter and hiked guidance, which is very different from almost every other drug company other than [inaudible] and it’s because of the weight loss. If the market weren’t that bad the stock would probably be up forty or fifty.”

While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.